UCL Institute of Cardiovascular Science
- Myocardial disease
- Structural heart disease
- Vascular disease
- Cardiovascular genetics
- Regenerative medicine
- Genetic epidemiology and translational cardiovascular genomics
- Preventions and outcomes
- News & events
- Contact us
Structural heart disease interventions
A new emerging field within adult Cardiovascular Medicine and one that has experienced exponential growth in recent years is Structural Heart Disease Intervention. This subspecialty of Cardiovascular Medicine focuses on developing and expanding transcatheter therapies for the treatment of both valvular and congenital heart disorders. Ultimately, these new treatment strategies can lead to shorter recovery time for patients.
our research is led by Dr Michael Mullen who has expertise in both structural
heart intervention and adult congenital heart disease. He has an extensive research portfolio and is
involved in the introduction of a number of new technologies including
first-in-man studies. He is named as an inventor on a number of patents of a
novel cardiac device and is focussed on continuing to develop new technologies
for the treatment of valvular and structural heart disease.
Key research activities
A number of
studies are underway to evaluate new technology for the protection against
stroke in patients undergoing transcatheter aortic valve implantation. Most notably Dr Mullen is the Chief
Investigator for a study evaluating the safety and efficacy of the SMT umbrella
collaborative project with the department of mechanical engineering at UCL is
supported by a grant of £1.5M from the Wellcome Trust. The aim is to develop a novel transcatheter
aortic valve implant using a self expanding frame and polymeric leaflets.
Dr Mullen is the Chief Investigator for the AIMS study (Aortic Irbesartan Marfan Syndrome Study).
This randomised controlled multi centre UK study is evaluating the effect of Irbesartan on aortic dilatation in patients with Marfan syndrome. The study is supported by a British Heart Foundation grant of £1.5M.
Dr Mullen has
undertaken a large body of research evaluating the pathophysiological role of
patent foramen ovale (PFO). Current studies include evaluations of the role of
PFO in stroke, chronic obstructive airways disease, sleep apnoea and migraine.